An Open Label Extension Study of Phase III Clinical Trial of Duloxetine in Patients With Fibromyalgia
Phase 3
- Conditions
- Fibromyalgia
- Registration Number
- JPRN-jRCT2080221803
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Participants who have completed the 15-week treatment in the preceding study (A Phase III clinical trial of duloxetine in participants with fibromyalgia), etc.
Exclusion Criteria
Participants with pain caused by diseases other than fibromyalgia and which possibly has any effect to the assessment, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of duloxetine in fibromyalgia pain modulation pathways?
How does duloxetine compare to Pregabalin in managing fibromyalgia symptoms long-term?
Which biomarkers correlate with duloxetine response in fibromyalgia patients?
What are the most common adverse events associated with duloxetine in fibromyalgia treatment?
Are there any combination therapies involving duloxetine for fibromyalgia under investigation?